Overview

A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of an experimental study drug (STA-4783) combined with an approved cancer medicine, paclitaxel, in the treatment of soft tissue sarcomas. Paclitaxel (Taxol®) has been approved and used in the United States since 1992.
Phase:
Phase 2
Details
Lead Sponsor:
Synta Pharmaceuticals Corp.